Fortrea Holdings is trading 5.16% up now at $18.64 after announcing on September 2, 2026, a definitive agreement to acquire Worldwide Clinical Trials’ Early Phase Services division for approximately $45 million.
- Adds Texas clinical pharmacology, bioanalytical and biospecimen-storage capabilities to Fortrea’s integrated Phase I–IV platform and early-stage capacity.
- Closing awaits regulatory/licensing approvals and related services agreements.
- No source explicitly attributes the live price move to announcement; timing and fit make it the clearest company-specific catalyst.